Follicular Lymphoma
338
74
108
109
Key Insights
Highlights
Success Rate
66% trial completion
Published Results
80 trials with published results (24%)
Research Maturity
109 completed trials (32% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
16.9%
57 terminated out of 338 trials
65.7%
-20.8% vs benchmark
11%
37 trials in Phase 3/4
73%
80 of 109 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 109 completed trials
Clinical Trials (338)
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Clonal Evolution in Follicular Lymphoma
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
SynKIR-310 for Relapsed/Refractory B-NHL
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Evaluation of Skin Tests in Biotherapy Allergies